Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 7/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918557 | 0.90 | LRRK2 (0.33) | KDM4EALDH1A1SMN1; SMN2NPC1JAK1 | |
| SCHEMBL9921974 | 0.82 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2JAK1SYKPOLB | |
| SCHEMBL9918555 | 0.79 | SYK (0.36) | ALDH1A1JAK1JAK3SYKPOLB | |
| SCHEMBL9918558 | 0.74 | HTT (0.41) | KDM4EALDH1A1SMN1; SMN2NPC1POLB | |
| SCHEMBL9918562 | 0.74 | SYK (0.47) | SYKPOLBPDE3BPDE3ALRRK2 | |
| SCHEMBL13386794 | 0.73 | SYK (0.53) | KDM4EALDH1A1SMN1; SMN2JAK1JAK3 | |
| SCHEMBL3280818 | 0.72 | SYK (0.45) | KDM4EALDH1A1SMN1; SMN2NPC1JAK1 | |
| SCHEMBL12833307 | 0.72 | LRRK2 (0.43) | SYKLRRK2 | |
| SCHEMBL9918560 | 0.71 | JAK2 (0.34) | JAK1JAK3SYKLRRK2 | |
| SCHEMBL9918545 | 0.71 | CSF1R (0.46) | ALDH1A1SMN1; SMN2NPC1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | KDM4E 477/4885ALDH1A1 1507/4885SMN1; SMN2 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.